SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
From Loner to Force to be reckoned with: Individual Accounts of Change - 2Instructions to Choose the Best Material Organization for a Fruitful Rooftop Substitution
- 3If you want a true taste of Italian paradise, head to Favignana
- 4Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
- 5Defeating An inability to embrace success in Scholarly world: Individual Victories
- IDF strikes Hamas terror cell operating near Israeli troops in northern Gaza
- I was about to film a movie with Glen Powell when my hair started falling out in clumps. Alopecia has made me unrecognizable as an actor.
- ‘Grit’ and relentless perseverance can take a toll on brain health − particularly for people facing social stresses like racism
- Scientist turns people’s mental images into text using ‘mind-captioning’ technology
- Merz says army could be involved in mine-clearing from Hormuz
- Blue Origin’s New Glenn rocket landed its booster on a barge at sea – an achievement that will broaden the commercial spaceflight market
- 35 million tons of food go to waste yearly in the US. Experts share tips to help stop it
- An Investigate of 6 Creative Specialty Mixed drinks
- The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
